Kos and Barr Announce Definitive Settlement Agreements

Kos Pharmaceuticals and Barr Pharmaceuticals announced that that they have signed co-promotion, licensing and manufacturing, and settlement and license agreements relating to the resolution of the patent litigation involving Kos' Niaspan products. The United States District Court for the Southern District of New York entered into a consent dismissal ending the pending litigation between the two companies. These arrangements have been established to provide benefits to millions of female patients who have multiple lipid disorders and are candidates for Kos' niacin-based pharmaceutical cholesterol products.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19667120&full=1)